Fixed combinations in the treatment of hypertension

Česká verzia

Authors: J. Špinar ¹; J. Vítovec ²; L. Špinarová ²; M. Bendová ³
Authors place of work: Interní kardiologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jindřich Špinar, CSc., FESC ¹; I. interní kardioangiologická klinika Lékařské fakulty MU a FN u sv. Anny – ICRC Brno, přednosta prof. MUDr. Jiří Vítovec, CSc., FESC ²; Nemocniční lékárna FN Brno, pracoviště Bohunice, vedoucí PharmDr. Tatiana Holubová ³
Published in the journal: Vnitř Lék 2012; 58(7 a 8): 215-222
Category: 60th Birthday prof. MUDr. Miroslav Souček, CSc.

Summary

We present an overview of current opinions on combination therapy and the role of fixed combinations in the treatment of hypertension as per the ESH/ESC and CSH guidelines of 2007 and the revised European guidelines of 2009. A renin-angiotensin system blocker (ACE-I or sartan) combined with a calcium channel blocker is the most frequently recommended combination, followed by renin-angiotensin system blocker and a diuretic and a calcium channel blocker and a diuretic. A fixed combination of a calcium channel blocker and a beta-blocker has now been also recommended. Higher patient compliance and thus better control of hypertension is the main advantage of fixed combinations. We present an overview of fixed combinations registered in the Czech Republic until May 2012.

Key words:
hypertension – combination therapy – fixed combinations

Zdroje

1. Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363–2369.

2. Widimský jr. J, Cífková R, Špinar J et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze – verze 2007. Doporučení České společnosti pro hypertenzi. Cor Vasa 2008; 50: K3–K16.

3. Widimský J jr., Cífková R, Špinar J et al. Doporučení diagnostických a léčebných postupů arteriální hypertenze – verze 2007. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2008; 1: 101–118.

4. Cífková R, Škodová Z, Bruthans J et al. Longitudinal trends in cardiovascular mortality and blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2007/2008. J Hypertens 2010; 28: 2196–2203.

5. Kettani FZ, Dragomir A, Côté R et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009; 40: 213–220.

6. Peters R, Beckett N, Forrete F et al. HYVET investigators. Incident dementia and blood pressure lowering inthe HYpertension in Very Elderly Trial cognitive function assement (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2008; 7: 683–689.

7. Mancia G, Laurent S, Agabiti-Rosei L et al. European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of hypertension Task Force document. J Hypertens 2009; 27: 2121–2158.

8. Bangalore S, Kamalakkannan G, Parkar S et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713–719.

9. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122: 290–300.

10. Blood Presure Lowering Trialist’ Colaboration: Effect of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 238: 1121–1128.

11. Vítovec J, Špinar J. Perindopril/indapamid – fixní kombinace. Remedia 2007; 17: 247–257.

12. Patel A. ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829–840.

13. Makita S, Abiko A, Naganuma Y et al. Efficacy of low-dose hydrochlorothiazide in combination with telmisartan on early morning blood pressure in uncontrolled hypertensive patients. Clin Exp Hypertens 2009; 31: 105–115.

14. Kalra S, Kalra B, Agrawal N. Combination therapy in hypertension: An update. Diabetol Metab Syndr 2010; 2: 44.

15. Souček M, Řiháček I, Fráňa P et al. Léčba hypertenze v rámci metabolického syndromu. Kardiol Rev 2010; 12: 73–76.

16. Nissen SE, Tuzcu EM, Libby P et al. CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–2225.

17. Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597–603.

18. Tobe S, Kawecka-Jaszcz K, Zannad F et al. Amlodipine added to quinapril vs quinapril alone for the treatment of hypertension in diabetes: the Amlodipine in Diabetes (ANDI) trial. J Clin Hypertens (Greenwich) 2007; 9: 120–127.

19. Dahlöf B, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906.

20. Poulter NR, Wedel H, Dahlöf B et al. ASCOT Investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907–913.

21. Bakris GL, Sarafidis PA, Weir MR et al. ACCOMPLISH Trial investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173–1181.

22. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417–2428.

23. Zou Z, Xu FY, Wang L et al. Antihypertensive and renoprotective effects of trandolapril//verapamil combination: a meta-analysis of randomized controlled trials. J Hum Hypertens 2011; 25: 203–210.

24. Řiháček I, Řiháčková E. Kardioprotektivní kombinace v léčbě hypertenze – beta-blokátory a blokátory kalciových kanálů typu dihydropyridinů. Causa Subita 2012; 15: 46–48.

25. Yusuf S, Teo KK, Pogue J et al. ONTARGET Investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–1559.

26. Gradman AH, Acevedo C. Evolving strategies for the use of combination therapy in hypertension. Curr Hypertens Rep 2002; 4: 343–349.

27. Špinar J, Vítovec J. Kombinační léčba hypertenze. Causa Subita 2012; 15: 10–13.

28. Hess G, Hill J, Lau H et al. Medication Utilization Patterns and Hypertension-Related Expenditures among Patients Who Were Switched from Fixed-Dose To Free-Combination Antihypertensive Therapy. PT 2008; 33: 652–666.

29. Deeks ED. Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension. Am J Cardiovasc Drugs 2009; 9: 411–418.